Abbott Laboratories
F:ABL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (19.7), the stock would be worth €113.04 (36% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.5 | €83.02 |
0%
|
| 3-Year Average | 19.7 | €113.04 |
+36%
|
| 5-Year Average | 19.1 | €109.39 |
+32%
|
| Industry Average | 12.9 | €73.8 |
-11%
|
| Country Average | 14.4 | €82.22 |
-1%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€166.8B
|
/ |
Apr 2026
$11.6B
|
= |
|
|
€166.8B
|
/ |
Dec 2026
$13.2B
|
= |
|
|
€166.8B
|
/ |
Dec 2027
$14.5B
|
= |
|
|
€166.8B
|
/ |
Dec 2028
$15.6B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Abbott Laboratories
F:ABL
|
166.7B EUR | 14.5 | 26.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.3B USD | 43.9 | 57.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
129.4B USD | 20.4 | 39.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.1B USD | 13.1 | 23.6 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
90.4B USD | 18.6 | 31.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.2B EUR | 11.5 | 20.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 24 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.5B USD | 31 | 43.9 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.2B USD | 10.1 | 25.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
33.8B USD | 11.6 | 16.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.9B USD | 15.6 | 22.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Abbott Laboratories
Glance View
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.